AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
Friday, 29 May 2015
AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly's VEGF Receptor 2 antiangiogenic cancer medicine.
Eating a Mediterranean diet could cut womb cancer risk
Wednesday, 27 May 2015
Women who eat a Mediterranean diet could cut their risk of womb cancer by more than half (57 per cent), according to a study published today in the British Journal of Cancer. The Italian researchers looked at the diets of over 5,000 Italian women to see how closely they stuck to a Mediterranean diet and whether they went on to develop womb cancer.
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment
Tuesday, 26 May 2015
Eureka Therapeutics Inc. and Boehringer Ingelheim announced have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology. Eureka Therapeutics will apply its proprietary human sequence antibody libraries and its unique technology platform to identify antibodies recognizing intracellular proteins, which represent approximately 90% of cancer-specific targets.
Discovery of a treatment to block the progression of multiple sclerosis
Monday, 25 May 2015
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.
AstraZeneca provides update on brodalumab development programme
Friday, 22 May 2015
Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
Thursday, 21 May 2015
Novartis announced today that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care.